Foley Hoag Represents Dicerna in Recent Collaborations
October 29, 2018
Foley Hoag LLP represented Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) in two collaboration agreements with Eli Lilly and Company (NYSE: LLY) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), both announced in the last week. Using Dicerna’s leading position in RNA interference (RNAi)-based therapeutics, these collaborations target neurodegeneration, pain and cardiometabolic indications in the case of Lilly and complement-mediated disease in the case of Alexion.
Headquartered in Cambridge, Mass., Dicerna is a biopharmaceutical company focusing on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. The company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented.
On October 29, 2018, Dicerna announced a global licensing and research collaboration with Eli Lilly and Company focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain.
On October 24, 2018, Dicerna entered into a collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNA interference therapies for complement-mediated diseases.
For more information, visit www.dicerna.com.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.